Physician
Internal Medicine
Dr. Bradley W. Blaser, MD
|
|
Give Review
Bradley W. Blaser, MD practices Internal Medicine. Bradley Blaser has written publications. He has 17 publications published with PubMed. The lastest paper is: 'Hyperlipidemia and Statin Use after Allogeneic Hematopoietic Stem Cell Transplantation.' He accepts all Medicare patients.
Publications
- Hyperlipidemia and Statin Use after Allogeneic Hematopoietic Stem Cell Transplantation.
- In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis.
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
- The PP2A inhibitor SET regulates natural killer cell IFN-gamma production.
- Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
- FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
- Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells.
- Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity.
- Tumor growth impedes natural-killer-cell maturation in the bone marrow.
- Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35.
- Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells.
- A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
- The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
- IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease.
- Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease.
- Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Schools
Ohio State University College of Medicine
Conditions Treated
- Anemia
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Drug Facts
| NPI NUMBER | 1407014194 | |
| NPPES Provider LastName | BLASER | |
| NPPES Provider FirstName | BRADLEY | |
| NPPES Provider ZIPCode | 021156110 | |
| NPPES Provider State | MA | |
| Specialty Description | Student in an Organized Health Care Education/Training Program | |
| Total Claim Count | 16.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1407014194 |
| Last Name Of The Provider | BLASER |
| First Name Of The Provider | BRADLEY |
| View All |
Similar Doctors
|
|
Dr. Jens G. Lohr, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Juan Godinez, MD |
|
|
Dr. Carlos J. Gonzalez Quesada, MD |
|
|
Dr. Katherine K. Clifton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael G. Silverman, MD |